

Neurology Medical Group of Diablo Valley  
400 Taylor Boulevard  
Suite 301  
Pleasant Hill, CA 94523  
Phone: 925-602-7060  
Fax: 925-602-7070

# Brad Allen Volpi , MD

## Certifications

Qualified Medical Examiner	2000
American Society of Neurosonology – Neurosonology	1992
American Board of Psychiatry and Neurology – Neurology	1988

## Licensure

Primary MD - G61017, California

## Academic Degrees

MD - University of Connecticut School of Medicine, Farmington, CT	1974 - 1978
BA - Psychology, University of California Berkeley, Berkeley, CA	1970 - 1974

## Residencies and Internships

Internship - Rotating, St. Francis Hospital and Medical Center, Hartford, CT	July 1978 - June 1979
Residency - Neurology, Yale University School of Medicine, New Haven, CT	July 1983 - June 1986

## Fellowships

Epilepsy - Merritt-Putnam Fellowship - Yale University School of Medicine, New Haven, CT	July 1986 - June 1987
--	-----------------------

## Professional Societies

California and Contra Costa County Medical Associations	1987 – present
American Academy of Neurology	1984 – present
American Society of Neurosonology	1992 – 1994
American Epilepsy Society	1987 – 1990
American Academy of Family Practitioners	1979 - 1983
American Medical Association	1979 - 1983
Johnston County, NC Medical Society	1979 - 1983

## Experience

Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Creek, CA	1987 - present
General Practice - National Health Service Corps, Johnson Matthews Medical Center, Benson, NC	1979 - 1983

## **Appointments**

Selected as an Expert Reviewer for the Medical Board of California Member – Quality Improvement Committee John Muir Health Network	2011 2002 - 2006
Member – Professional Liability Committee, Alameda-Contra Costa Medical Association	1994 - present
Chairman, Medical Education Committee – John Muir Medical Center, Walnut Creek, CA	1997 - 1998
Chief of Neurology - John Muir Medical Center, Walnut Creek, CA	1993 - 1995
Attending Physician, Inpatient, Outpatient & Consult Services – Department of Neurology, Yale University School of Medicine, New Haven, CT	1986 - 1987
Instructor in Neurology - Yale University School of Medicine, New Haven, CT	1986 - 1987
Medical Advisor – American Cancer Society Johnston County, NC Chapter	1982 - 1983
Quality Assurance & Infection Control Committee - Johnston Memorial Hospital, Smithfield, NC	1979 - 1983
Admitting Physician - Johnston Memorial Hospital, Smithfield, NC	1979 - 1983
Trainee & Clerk – Indian Health Services, Taholah Community Health Center, Quinault Reservation, WA	1977

## **Awards**

Merritt-Putnam Fellowship Award - Epilepsy Foundation of America,	1986 - 1987
Phi Beta Kappa – University of California Berkeley, Berkeley, CA	1974
BA Degree, Psychology, Great Distinction - University of California Berkeley, Berkeley, CA	1974

## **Current Hospital Affiliations**

John Muir Medical Center - Walnut Creek, CA  
John Muir Medical Center - Concord, CA

## **Research Activities**

### PRINCIPAL INVESTIGATOR

Partial-Onset Epilepsy: A Cross-Sectional Survey of Patient Reported Functional Health and Well-Being	2003 – 2004
E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease	2003– 2004
Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolus Events in Patients with Atrial Fibrillation (SPORTIF V)	2000 – 2003
Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Mono- therapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: <u>T</u> rial to <u>A</u> ssess and <u>R</u> efine <u>G</u> lobal <u>E</u> pilepsy <u>T</u> reatment)”	1999 – 2000

"Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease."	1999 – 2000
Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures."	1998 – 1999
Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures."	1998 – present
"Open Label, Multicenter Trial of the Safety and Efficacy of Aricept in the Treatment of Alzheimer's Disease."	1996
"Landmark Investigation of Compound in the Treatment of Epilepsy."	1993.
"Cognex Access Program, Phase IV."	1992
Relation of Sleep and Epilepsy, Performed at Yale and the West Haven VA Epilepsy Center.	1986 – 1987
<i>SUBINVESTIGATOR</i>	
A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PROFESS)	2003 – present
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT II)	2003 – present
A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE)	2003 – 2007
A Prospective, 26-Week, Open-label, Multi-center Study Evaluating the Efficacy And Safety of Exelon (rivastigmine tartrate) 3 – 12 mg/day in Patients with Mild To Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept® (donepezil) Treatment	2003 – 2004
A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanrole versus Placebo in Patients with Early Parkinson's Disease	2003 - 2006
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)	2003 – 2006
A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX ® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF)	2003 – 2004
Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke	2002 – 2006
A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity	2002

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole versus Placebo or Ropinerole in Patients with Early Parkinson's Disease	2002 – 2003
Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-95666E	2002 – 2005
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH)	2001 – 2004
A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke	2001 – 2002
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke. (ARTIST MRI)	2001 - 2003
Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo. (ARTIST +)	2001 - 2003
Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist	2001
Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain	2001
Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease	2000 – 2002
Acute Ischemic Stroke Protocol 161-106, Phase II	2000 – 2000
"Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO), Phase III."	1999 – 2001
"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23F2G (LeukArrest™) in Patients with Acute Ischemic Stroke."	1999 – 2000
"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy." 1998 – present	1998 – 2000
The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke."	1997 – 2000
The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage."	1997 – 1999
The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke."	1997 – 1999

"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Prosaptide When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus."	1998 – 1999
"t-PA in Acute Stroke Study, less than 3 hrs." Phase IV."	1997 – 1999
An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting."	1997 – 1999
"Lubeluzole Int-13 Acute Stroke Study, Phase III."	1997
"Enlimomab Acute Stroke Study, Phase III."	1995 – 1996
"DHE 454 Migraine Study, Phase III."	1995